PharmaCielo Ltd. PCLOF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.00M | 523.80K | 434.80K | 645.50K | 233.10K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.00M | 523.80K | 434.80K | 645.50K | 233.10K |
| Cost of Revenue | 629.90K | 320.60K | -285.20K | 1.01M | 277.00K |
| Gross Profit | 374.40K | 203.20K | 720.00K | -360.60K | -43.90K |
| SG&A Expenses | 825.60K | 497.60K | 230.60K | 1.56M | 600.90K |
| Depreciation & Amortization | 74.60K | 5.80K | 2.90K | 35.30K | 14.50K |
| Other Operating Expenses | -41.60K | 718.20K | -653.80K | -33.40K | -128.60K |
| Total Operating Expenses | 1.49M | 1.54M | -705.50K | 2.57M | 763.80K |
| Operating Income | -484.30K | -1.02M | 1.14M | -1.92M | -530.70K |
| Income Before Tax | -1.04M | -946.30K | 292.20K | -1.01M | -940.30K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.04M | -946.30K | 292.20K | -1.01M | -940.30K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.04M | -946.30K | 292.20K | -1.01M | -940.30K |
| EBIT | -484.30K | -1.02M | 1.14M | -1.92M | -530.70K |
| EBITDA | -409.70K | -390.70K | 1.45M | -1.86M | -321.30K |
| EPS Basic | -0.01 | -0.01 | 0.00 | -0.01 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 |
| EPS Diluted | -0.01 | -0.01 | 0.00 | -0.01 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 |
| Average Basic Shares Outstanding | 207.00M | 189.98M | 187.98M | 187.98M | 187.98M |
| Average Diluted Shares Outstanding | 207.00M | 189.98M | 187.98M | 187.98M | 187.98M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |